What this means
Researchers plan to follow adults aged 18 to 74 who are at high risk or have had a heart attack. They will collect blood, urine, and stool samples and track health outcomes. This is a plan, so it does not yet show whether these steps help people.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 18–74
- Where
- 1 site
The science
- Registered title
- Prospective Lifespan Cohort of Myocardial Infarction
- Trial ID
- NCT07471763 ↗
- Phase
- Not applicable
- Study type
- observational
- Conditions
- Acute Myocardial Infarction (AMI), Stable Angina, Unstable Angina
- Sponsor
- Fujian Provincial Hospital
- Ages
- 18 Years to 74 Years
- Dates
- First posted Mar 13, 2026 · updated Mar 25, 2026
Registry summary
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.
The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.
The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Sites (1)
- Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China
